RUBY Stock Overview
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rubius Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.057 |
52 Week High | US$0.38 |
52 Week Low | US$0.0032 |
Beta | 2.21 |
1 Month Change | 198.43% |
3 Month Change | 251.85% |
1 Year Change | -64.38% |
3 Year Change | -99.32% |
5 Year Change | -99.63% |
Change since IPO | -99.76% |
Recent News & Updates
Recent updates
Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03
Aug 09Rubius: Poor Data, Punishing Environment, Beaten Stock
Jun 19Rubius Looks Attractive Before AACR Data Readout
Mar 21Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?
Oct 28Our Read On Rubius Therapeutics
Jul 11Rubius Therapeutics EPS beats by $0.02
May 10Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?
Feb 25Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Rubius Therapeutics EPS misses by $0.01
Nov 09Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers
Oct 28Shareholder Returns
RUBY | US Biotechs | US Market | |
---|---|---|---|
7D | 2.7% | -3.3% | -0.4% |
1Y | -64.4% | -2.7% | 24.8% |
Return vs Industry: RUBY underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: RUBY underperformed the US Market which returned 22.4% over the past year.
Price Volatility
RUBY volatility | |
---|---|
RUBY Average Weekly Movement | 54.6% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 17.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RUBY's share price has been volatile over the past 3 months.
Volatility Over Time: RUBY's weekly volatility has increased from 34% to 55% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 6 | Craig Jalbert | www.rubiustx.com |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Rubius Therapeutics, Inc. Fundamentals Summary
RUBY fundamental statistics | |
---|---|
Market cap | US$5.16m |
Earnings (TTM) | -US$179.67m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RUBY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RUBY income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$179.67m |
Earnings | -US$179.67m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.99 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did RUBY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/01/03 13:52 |
End of Day Share Price | 2023/12/29 00:00 |
Earnings | 2022/12/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Schmidt | Guggenheim Securities, LLC |
Andrew Fein | H.C. Wainwright & Co. |
Michael Yee | Jefferies LLC |